Home » Newsletters » BioWorld Science

BioWorld Science

March 20, 2012

View Archived Issues

Sangamo cell therapy increases CD4+ T-cell counts in patients with HIV

Novacta Biosystems develops novel candidate antibacterials

Phase I trial assesses interaction between diabetes therapies

Novel first-in-human data presented on Medimmune cancer immunotherapy

New data highlight role of lymphopoietin in chronic rhinosinusitis with nasal polyps

U.S. study links SNPs to complications after subarachnoid hemorrhage

Cartagenia enters partnership for rare epilepsy syndromes

Merck & Co. enters into collaboration to create new institute

Ampio provides update on Optina trial

Once-daily tramadol capsule launched in Canada for chronic pain

Alnylam launches phase I trial of transthyretin-mediated amyloidosis therapy

Provectus Pharmaceuticals reports topline phase II data on PH-10

QRxPharma and Actavis sign new licensing agreement

CUNY to validate diagnostic antibodies

Novel GPR124 receptor agonists designed in U.S.

New potential flu therapies presented

New nicotinic acetylcholine receptor ligands synthesized

Boehringer Ingelheim Pharma divulges new MPGES-1 inhibitors

Santhera reports novel mitochondrial function modulators

Avaxia receives second NIH grant for oral IBD immunotherapeutic

Merck & Co. to discontinue development of vernakalant formulation

AstraZeneca and Targacept give update on TC-5214 development

First once-daily 24-hour LABA for COPD maintenance launched in U.S.

Enrollment complete in phase III trials of allergy immunotherapy

Cellceutix enters collaboration agreement to support Kevetrin development

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...